

Special Issue

Vaccine Related Immune Responses

Message from the Guest Editors

The use of vaccination to prevent infectious diseases was described long before establishing the fundamental dogmas of the immune system. Vaccines activate the immune system and generate memory T and B lymphocytes that "remember" the disease-causing agents. Upon encountering these pathogens later, the immune system will mount a rapid and robust immune response to antigens it has previously experienced, thereby preventing disease or reducing its severity. For most vaccines, more than one dose is necessary to provide long-lasting protection. Since the advent of recombinant DNA technology, vaccines have become the mainstay of protection against several infectious and non-infectious diseases. How a vaccine stimulates the immune system depends on many factors, such as the nature of the antigens, the route of administration, and the adjuvant present in the vaccines. This Special Issue aims to collect recent research related to vaccine-related immune responses, including recent advances in mRNA vaccines. We hope to provide a broad overview of how different vaccines work and help understand some new techniques and their utilization in vaccinology.

Guest Editors

Dr. Abhisek Bhattacharya
National Cancer Institute (NCI), National Institutes of Health (NIH),
Bethesda, MD 20814, USA

Dr. Zhongmei Zhang
National Cancer Institute (NCI), Bethesda, MD, USA

Deadline for manuscript submissions

closed (10 June 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/104052

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).